Blood Biomarker of Alzheimer's Disease (AD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

21 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-12

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for stratification of Alzheimer's disease patients and healthy volunteers. This study may lead to future blood tests that may help earlier diagnosis of Alzheimer's disease and detect the disease progression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Blood-based Biomarkers for Diagnosis of Alzheimer's

NCT05187819

Dementia Alzheimers

RECRUITING NA

Study to Understand Novel Biomarkers in Researching Dementia

NCT06547099

Alzheimer Disease Mild Cognitive Impairment Dementia

RECRUITING

Blood-brain Barrier Permeability in Alzheimer's Disease

NCT01574456

Alzheimer's Disease

COMPLETED

Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558

NCT01217021

Alzheimer Disease

COMPLETED EARLY_PHASE1

Assess Fibrin in Brains With AD/ADRD

NCT05336695

Alzheimer Disease Dementia of Alzheimer Type

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Alzheimer's Patients

No interventions assigned to this group

Healthy Volunteers

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Alzheimer's Disease Patients:

* 50 years and older
* AD patient who is seen at the Memory Disorders Clinic
* AD diagnosis
* Non smoking
* No cancer treatment in the last 5 years
* Informed consent from the patient or the patient's legally authorized representative (LAR)
* Patient and/or LAR able to read and speak English

Healthy Control Participants:

* 50 years and older
* Non smoking
* No cancer treatment in the last 5 years
* Age matched to AD subject
* Able to read and speak English

Exclusion Criteria

Alzheimer's Disease Patients:

* Known additional neurological disease

Healthy Control Participants:

* Neurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's)

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes